Astragaloside IV reduces cardiac oxidation and improves left ventricular diastolic dysfunction

25 August 2018 (00:00 - 00:00)

Organised by:

Sign in to view the resources

About the speaker

Doctor Qiongying Wang

Lanzhou University Second Hospital, Lanzhou (China)

21 More presentations in this session

Presentation thumbnail

Effects of mineralocorticoid receptor antagonists on diastolic function and exercise capacity in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials

Associate Professor H. Fukuta (Nagoya, JP)

Presentation thumbnail

Prognostic value of soluble ST2 biomarker in heart failure patients with preserved ejection fraction

Doctor K. Kopeva (Tomsk, RU)

Abstract Slides

Presentation thumbnail

Long non coding RNA levels in hypertensive patients with heart failure with preserved ejection fraction and their relation to their functional capacity

Associate Professor M. Marketou (Heraklion, GR)

Abstract Slides

Presentation thumbnail

Morphological and functional changes in cardiovascular system in heart failure with preserved ejection fraction.

Doctor M. Kurkina (Moscow, RU)

Abstract Slides

Presentation thumbnail

criteria derived from end-systolic pressure-volume relation applied to the study of heart failure

Professor R. Shoucri (Kingston, CA)

Abstract Slides

Access the full session

Session thumbnail

Poster Session 4 - Chronic heart failure – pathophysiology and mechanisms

The Event

ESC Congress 2018

25 August - 29 August 2018

You may be interested in

Congress Presentation

Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.

Congress Presentation

Pharmacotherapy in HFpEF: where do cardiometabolic drugs fit in?

Congress Session

Clinical phenotypes of heart failure with preserved ejection fraction

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources